• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用聚丙烯腈膜的无肝素血液透析

Heparin-free hemodialysis with a polyacrylonitrile membrane.

作者信息

Barth R H, Sodden S, Berlyne G M

机构信息

Veterans Administration Medical Center, SUNY Health Science Center, Brooklyn 11209.

出版信息

ASAIO Trans. 1989 Jul-Sep;35(3):597-600. doi: 10.1097/00002480-198907000-00139.

DOI:10.1097/00002480-198907000-00139
PMID:2597544
Abstract

The low in vitro thrombogenicity of polyacrylonitrile (AN-69) membrane may offer the possibility of performing hemodialysis (HD) with little or no heparin. The authors sought to reduce heparin dosage using AN-69 dialyzers at blood flows of 400 to 600 ml/min. Over a 90 day period, 2228 HDs were performed: 1531 (69%) with AN-69, 528 (24%) with regenerated cellulose (RC), and 169 (8%) with cellulose acetate (CA) dialyzers. Two hundred and eighty-three HDs were performed without systemic heparin; blood compartments were prerinsed with 2,000 U heparin in 1,000 ml of 0.9% saline. Saline flushes were used in cases of rising venous drip chamber pressures or visible clotting. Incidence of clotting overall in AN-69 HDs was 0.52% (8/1531), 2.8% (15/528) with RC, and 11.2% (19/169) with CA. In heparin-free HDs, incidence with AN-69 was 1.3% (3/230), 28.6% with RC (4/14), and 25.6% with CA (10/39). AN-69 remained less thrombogenic when HDs were stratified by blood flow rate and vascular access was used. Urea clearance was no different in conventional and heparin-free treatments. Blood flow rates of 400 ml/min or higher had an independent antithrombogenic effect. It was concluded that the combination of high blood flow with AN-69 membrane allows marked reduction of HD heparin dose and safe routine use of heparin-free HD.

摘要

聚丙烯腈(AN - 69)膜的低体外血栓形成性可能为进行很少或不使用肝素的血液透析(HD)提供了可能性。作者试图在血流量为400至600 ml/min的情况下,使用AN - 69透析器减少肝素剂量。在90天的时间里,共进行了2228次血液透析:1531次(69%)使用AN - 69透析器,528次(24%)使用再生纤维素(RC)透析器,169次(8%)使用醋酸纤维素(CA)透析器。283次血液透析未使用全身肝素;血液腔室先用1000 ml 0.9%盐水中的2000 U肝素进行预冲洗。在静脉滴注室压力升高或出现可见凝血的情况下使用盐水冲洗。AN - 69血液透析中总体凝血发生率为0.52%(8/1531),RC为2.8%(15/528),CA为11.2%(19/169)。在无肝素血液透析中,AN - 69的发生率为1.3%(3/230),RC为28.6%(4/14),CA为25.6%(10/39)。当根据血流量分层并使用血管通路时,AN - 69的血栓形成性仍然较低。常规治疗和无肝素治疗的尿素清除率没有差异。400 ml/min或更高的血流量具有独立的抗血栓形成作用。得出的结论是,高血流量与AN - 69膜相结合可显著降低血液透析肝素剂量,并能安全地常规使用无肝素血液透析。

相似文献

1
Heparin-free hemodialysis with a polyacrylonitrile membrane.使用聚丙烯腈膜的无肝素血液透析
ASAIO Trans. 1989 Jul-Sep;35(3):597-600. doi: 10.1097/00002480-198907000-00139.
2
Low-dose heparinization can be used with DEAE-cellulose hemodialysis membranes.低剂量肝素化可用于二乙氨基乙基纤维素血液透析膜。
ASAIO Trans. 1990 Jul-Sep;36(3):M321-4.
3
Evaluation of dialyzers used in shortened dialysis.
ASAIO Trans. 1989 Jul-Sep;35(3):338-40. doi: 10.1097/00002480-198907000-00053.
4
[Clinical usefulness of heparin-coated dialyzers].[肝素涂层透析器的临床效用]
Przegl Lek. 2014;71(8):430-2.
5
The clinical evaluation of low-dose heparin in haemodialysis: a prospective study using the heparin-coated AN69 ST membrane.低剂量肝素在血液透析中的临床评估:一项使用肝素涂层AN69 ST膜的前瞻性研究。
Nephrol Dial Transplant. 2008 Jun;23(6):2003-9. doi: 10.1093/ndt/gfm888. Epub 2007 Dec 21.
6
Hemodialysis without heparin: a randomized, controlled, crossover study of two dialysis membranes (AN69ST and polysulfone F60).无肝素血液透析:两种透析膜(AN69ST和聚砜F60)的随机对照交叉研究
Int J Artif Organs. 2011 Dec;34(12):1165-71. doi: 10.5301/ijao.5000033.
7
Non-heparin hemodialysis with oral administration of newly developed antiplatelet agent.
ASAIO Trans. 1990 Jul-Sep;36(3):M212-5.
8
Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane.使用肝素涂层聚丙烯腈膜进行血液透析时的最佳抗凝策略。
Nephrol Dial Transplant. 2003 Oct;18(10):2097-104. doi: 10.1093/ndt/gfg272.
9
Clotting by heparin of hemoaccess for hemodialysis in an end-stage renal disease patient.
Am J Kidney Dis. 1995 Apr;25(4):642-7. doi: 10.1016/0272-6386(95)90138-8.
10
Biocompatibility and clinical performance of a new modified cellulose membrane.新型改性纤维素膜的生物相容性及临床性能
Clin Nephrol. 1986;26 Suppl 1:S22-9.

引用本文的文献

1
Critical care in uraemic children.尿毒症患儿的重症监护
Pediatr Nephrol. 1992 Jan;6(1):88-95. doi: 10.1007/BF00856850.